BIOFORCE NANOSCIENCES HOLDINGS, INC.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Apr 2026 | Mar 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $118.6K | — | — | $12.0K | — | — | $10.2K |
| Operating Income | — | $-262.3K | — | — | $-117.7K | — | — | $-115.9K |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-262.3K | — | — | $-117.7K | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $238.7K | — | — | $-102.4K | — | — | $-115.9K |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $0.01 | — | — | $0.00 | — | — | $0.00 |
| EPS (Diluted) | — | $0.01 | — | — | $0.00 | — | — | $0.00 |
| Shares Outstanding (Basic) | 33.5M | 33.5M | 33.5M | 33.5M | 33.5M | 33.5M | 33.5M | 33.5M |
| Shares Outstanding (Diluted) | 33.5M | 33.5M | 33.5M | 33.5M | 33.5M | 33.5M | 33.5M | 33.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |
Obvious prospects for physical growth in a business do not translate into obvious profits for investors.